Terpenology Conditions
Record No. 14Pennsylvania Medical Cannabis

Pennsylvania Medical Cannabis

Perimenopause

What the research actually supports, and what it does not.

Pennsylvania program
Not a Pennsylvania qualifying condition
Cannabinoid evidence
Human observational B
one survey; no trial
Terpene evidence
Animal and cell models C–D
preclinical, and not perimenopause-specific
Fit score confidence
Low; symptom-routed only
Terpenes examined
Linalool, Myrcene, Limonene, Caryophyllene

What women mostly use cannabis for in perimenopause is sleep and mood, and what the research offers is a single survey and a stack of borrowed preclinical claims. Honest help here means routing you to the symptom, not the life stage.

What patients are managing

Perimenopause is not a qualifying condition in Pennsylvania's medical program. Patients navigating it often reach for cannabis for the disrupted sleep, the mood swings, and the body discomfort, less so for hot flashes. Those are real symptoms with their own evidence, and the most honest thing this page can do is point at them directly rather than at perimenopause as a target.

What the research supports: cannabinoids

The cannabinoid evidence is one survey. A 2022 study of 258 peri- and postmenopausal women found most were using cannabis and most were aiming at sleep and mood or anxiety, with hot flashes far down the list. That is self-reported use, not a controlled trial and not resolved to any terpene. There is no perimenopause-specific cannabinoid trial, and commentary notes long-term safety data in midlife women are lacking.

What the research supports: terpenes

There is no perimenopause-specific terpene evidence. The terpenes named for it, linalool and myrcene for sleep, limonene for daytime mood, beta-caryophyllene for discomfort, rest on general preclinical reviews that conclude the clinical trials are lacking. No study connects any specific terpene to a measured perimenopause outcome in humans. The rationale is borrowed from the sleep and anxiety literature.

What the research does not support

No study ties any terpene to a perimenopause outcome, and the cannabinoid evidence is a single survey of what women report using, not what works. A confident perimenopause Fit score would dress up sleep and anxiety extrapolations as menopause science. The honest move is to say that plainly and send you to the symptom evidence instead.

How Terpenology scores this

Terpenology does not show a confident perimenopause score. Any signal is routed through the sleep and mood or anxiety evidence, handled under those conditions, and flagged as symptom-based rather than a validated perimenopause treatment. The app echoes the honest caveat that this is extrapolation, not perimenopause-tested science.

Terpenes worth reading about

Linalool · Myrcene · Limonene · Caryophyllene

Terpenology is educational, not medical advice. Terpene effects are tendencies commonly reported by patients and early research, never guaranteed outcomes. Nothing here is a substitute for the care of your certifying physician, your pharmacist, or the specialist treating your condition.

Terpenology
Medicate Smarter, Not Harder™